Brief: Ocugen Announces Dosing Completion Of Subjects With Geographic Atrophy In Cohort 1 Of Phase 1/2 Clinical Trial Evaluating Safety, Efficacy Of OCU410
13/03/2024 12:11
March 13 (Reuters) - Ocugen Inc OCGN.O :
* OCUGEN, INC. ANNOUNCES DOSING COMPLETION OF SUBJECTS WITH
GEOGRAPHIC ATROPHY IN COHORT 1 OF PHASE 1/2 CLINICAL TRIAL
EVALUATING THE SAFETY AND EFFICACY OF OCU410
Source text for Eikon: ID:nGNXTCfkh
Further company coverage: OCGN.O
((Reuters.Briefs@thomsonreuters.com;))